Clene Competitors
| CLNN Stock | USD 5.04 0.45 9.80% |
Clene vs Connect Biopharma Correlation
Very weak diversification
The correlation between Clene Inc and CNTB is 0.4 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Clene Inc and CNTB in the same portfolio, assuming nothing else is changed.
Moving together with Clene Stock
Moving against Clene Stock
| 0.85 | DRTS | Alpha Tau Medical | PairCorr |
| 0.77 | GXEA | Galapagos NV | PairCorr |
| 0.73 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.69 | DSGN | Design Therapeutics | PairCorr |
| 0.66 | EQ | Equillium | PairCorr |
Clene Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Clene and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Clene and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Clene Inc does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Clene Stock performing well and Clene Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Clene's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MGNX | 2.60 | 0.23 | 0.06 | 0.47 | 2.69 | 6.47 | 24.44 | |||
| OVID | 4.30 | 0.12 | 0.05 | 0.14 | 4.91 | 9.70 | 36.13 | |||
| COYA | 2.76 | (0.35) | 0.00 | (0.47) | 0.00 | 4.70 | 18.43 | |||
| ORMP | 2.70 | 0.46 | 0.20 | 0.31 | 2.15 | 6.98 | 17.67 | |||
| WHWK | 3.30 | 0.59 | 0.15 | 0.98 | 3.29 | 6.98 | 21.49 | |||
| CNTX | 4.24 | 1.43 | 0.29 | (3.39) | 3.55 | 9.59 | 24.11 | |||
| ZNTL | 5.06 | 1.03 | 0.20 | 0.59 | 4.64 | 17.36 | 49.29 | |||
| STTK | 3.46 | 1.20 | 0.34 | 2.40 | 2.85 | 6.42 | 27.88 | |||
| PLRX | 2.58 | (0.35) | 0.00 | (0.27) | 0.00 | 4.59 | 18.94 | |||
| CNTB | 4.30 | 0.09 | 0.00 | (0.62) | 4.85 | 9.23 | 34.64 |
Cross Equities Net Income Analysis
Compare Clene Inc and related stocks such as MacroGenics, Ovid Therapeutics, and Coya Therapeutics Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGNX | 6.7 M | 6.7 M | 8.4 M | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (117.8 M) | (190.9 M) | (120 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
| OVID | (447 K) | (447 K) | (447 K) | (447 K) | (447 K) | (13.2 M) | (22.4 M) | (64.8 M) | (52 M) | (59.3 M) | (80.7 M) | 122.8 M | (51.4 M) | (52.3 M) | (26.4 M) | (23.8 M) | (25 M) |
| COYA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.9 M) | (12.2 M) | (8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| ORMP | (50 K) | (1.6 M) | (3.3 M) | (4.2 M) | (5.7 M) | (7.2 M) | (11 M) | (10.5 M) | (12.7 M) | (14.4 M) | (11.5 M) | (22.2 M) | (37.8 M) | 5.5 M | (19.1 M) | (17.2 M) | (16.3 M) |
| WHWK | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (3.5 M) | (110.1 M) | (60.5 M) | (65.8 M) | (63.7 M) | (57.3 M) | (60.2 M) |
| CNTX | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (24.6 M) | (7.5 M) | (7.5 M) | 6.6 M | (10.5 M) | (14.8 M) | (24 M) | (26.7 M) | (30.7 M) | (32.3 M) |
| ZNTL | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (45.7 M) | (117.8 M) | (158.7 M) | (236.8 M) | (292.2 M) | (165.8 M) | (149.3 M) | (156.7 M) |
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (35.4 M) | (45 M) | (100.6 M) | (87.3 M) | (75.4 M) | (67.9 M) | (71.3 M) |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
Clene Inc and related stocks such as MacroGenics, Ovid Therapeutics, and Coya Therapeutics Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Clene Inc financial statement analysis. It represents the amount of money remaining after all of Clene Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Clene Competitive Analysis
The better you understand Clene competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Clene's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Clene's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Clene Competition Performance Charts
Five steps to successful analysis of Clene Competition
Clene's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Clene Inc in relation to its competition. Clene's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Clene in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Clene's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Clene Inc, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Clene position
In addition to having Clene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tips ETFs Thematic Idea Now
Tips ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 35 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Clene Correlation with its peers. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Will Biotechnology sector continue expanding? Could Clene diversify its offerings? Factors like these will boost the valuation of Clene. Projected growth potential of Clene fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Clene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.614 | Earnings Share (3.44) | Revenue Per Share | Quarterly Revenue Growth (0.83) | Return On Assets |
Understanding Clene Inc requires distinguishing between market price and book value, where the latter reflects Clene's accounting equity. The concept of intrinsic value - what Clene's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Clene's price substantially above or below its fundamental value.
It's important to distinguish between Clene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Clene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Clene's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.